Our expanding knowledge of microbial mechanisms is challenging the notion of “good” versus “bad” microbes and encouraging a better understanding of their roles in various contexts before their widespread therapeutic and clinical application. The intestinal microbe Akkermansia muciniphila, a promising probiotic with an emerging cautionary tale, best highlights this challenge.
